Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome

Phase 2 Completed 15 enrolled Lexicon Pharmaceuticals

RandomizedSingle-groupOpen-labelTreatment

Summary

The purpose of the study is to evaluate the safety and tolerability of orally administered telotristat etiprate (LX1606) in participants with symptomatic carcinoid syndrome.

Timeline

Start: 2010-06-15
Primary completion: 2014-02-12
Completion: 2014-02-12

Publications

Pavel M, Horsch D, Caplin M, Ramage J, Seufferlein T, Valle J, Banks P, Lapuerta P, Sands A, Zambrowicz B, Fleming D, Wiedenmann B. Telotristat etiprate for carcinoid syndrome: a single-arm, multicenter trial. J Clin Endocrinol Metab. 2015 Apr;100(4):1511-9. doi: 10.1210/jc.2014-2247. Epub 2015 Jan 30.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Telotristat etiprate	Unknown	150 mg	Oral
Subject	Telotristat etiprate	Unknown	250 mg	Oral
Subject	Telotristat etiprate	Unknown	350 mg	Oral
Subject	Telotristat etiprate	Unknown	500 mg	Oral

Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome

Summary

Timeline

Publications

Drugs

Indications